Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 13.33 USD -0.45% Market Closed
Market Cap: 345.9m USD

Net Margin
Cartesian Therapeutics Inc

-121.5%
Current
-245%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-121.5%
=
Net Income
-42.5m
/
Revenue
35m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Cartesian Therapeutics Inc
NASDAQ:RNAC
345.7m USD
-121%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
129.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Cartesian Therapeutics Inc
Glance View

Market Cap
345.7m USD
Industry
Biotechnology

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.

RNAC Intrinsic Value
0.18 USD
Overvaluation 99%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-121.5%
=
Net Income
-42.5m
/
Revenue
35m
What is the Net Margin of Cartesian Therapeutics Inc?

Based on Cartesian Therapeutics Inc's most recent financial statements, the company has Net Margin of -121.5%.

Back to Top